StockData
Medtronic plc logo

Medtronic plc (MDT) operating KPIs

MDTNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends April 24
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 3, 2026Score 19/303% below fair value
$96.54−0.57 (-0.59%)

Close on Oct 30, 2026Market cap $123.49BP/E 23.7Yield 2.94%

KPIs

Operating metrics that drive Medtronic's business · fiscal year ends Last Friday of April (52/53-week fiscal year; FY2026 ended April 24, 2026; Q1 FY2027 14-week quarter ended July 31, 2026)

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Medtronic's fiscal year ends Last Friday of April (52/53-week fiscal year; FY2026 ended April 24, 2026; Q1 FY2027 14-week quarter ended July 31, 2026) — Q1 FY27 = May–Jul 2026.

Column labels
Add to chartMetric
Q1 FY27
2026-07-31
Q4 FY26
2026-04-30
Q3 FY26
2026-01-31
Q2 FY26
2025-10-31
Q1 FY26
2025-07-31
Q4 FY25
2025-04-30
Q3 FY25
2025-01-31
Q2 FY25
2024-10-31
Q1 FY25
2024-07-31
Q4 FY24
2024-04-30
Q3 FY24
2024-01-31
Q2 FY24
2023-10-31
Worldwide New Insulin Pumps Sold (thousands of units)(M)
34.441.93932.131.94336.933.931.5
Global CGM Sensor Attachment Rate (%)(%)
69.0%68.0%67.0%65.0%64.0%63.0%61.0%59.0%57.0%
Diabetes Net Sales by Product Category ($M)($M)4
843837790752723724687682623
CGM Sensors & Transmitters Revenue ($M)($M)
431420390383360345330334304
Infusion Sets & Reservoirs (Pump Consumables) Revenue ($M)($M)
261249244234229223213210209
Durable Insulin Pumps Hardware Revenue ($M)($M)
144146151131119154136128123
Smart Pens & Other Diabetes Products Revenue ($M)($M)
7225415289-13
Diabetes Portfolio (Consolidated Segment) — Worldwide Revenue ($M)($M)7
843837796757721728694686647660640610
Medtronic Consolidated — Worldwide Revenue ($M)($M)8
9,7569,8079,0178,9618,5788,9278,2928,4037,9158,5898,0897,984
Consolidated Gross Margin Pricing Realization Benefit YoY (bps)(bps)
3030303030
Medtronic Consolidated — Organic Revenue Growth YoY (%)(%)
13.7%6.6%6.0%5.5%4.8%5.4%4.1%5.0%5.3%5.4%4.6%5.0%
Medtronic Consolidated — Foreign Currency Impact ($M)($M)
57308243111162-96-10445-93-756885
Medtronic Consolidated — Reported Revenue Growth YoY (%)(%)
13.7%9.9%8.7%6.6%8.4%3.9%2.5%5.3%2.8%0.5%4.7%5.3%
Medtronic Consolidated — U.S. Revenue ($M)($M)1
4,9064,8694,4934,5164,2244,5474,2374,3044,0824,3434,1204,175
Medtronic Consolidated — International Revenue ($M)($M)2
4,8504,9384,5244,4454,3544,3804,0554,0993,8324,2463,9683,809
Medtronic Consolidated — Non-U.S. Developed Markets Revenue (Legacy through FY2024Q4, $M)($M)1
2,6742,4732,368
Medtronic Consolidated — Emerging Markets Revenue (Legacy through FY2024Q4, $M)($M)1
1,5721,4951,441
Cardiovascular Portfolio — Worldwide Revenue ($M)($M)9
3,9273,7973,4573,4363,2853,3363,0373,1023,0073,1302,9292,923
Cardiac Ablation Solutions (CAS / PFA) — Global Organic Growth YoY (%)(%)2
88.0%78.0%80.0%71.0%
Cardiac Ablation Solutions (CAS) — U.S. Organic Growth YoY (%)(%)
139.0%124.0%137.0%
Cardiac Ablation Solutions (CAS) — U.S. Market Share Gain YoY (percentage points)(%)
9.0%8.0%4.0%
Cardiac Rhythm Management (CRM) — Global Organic Growth YoY (%)(%)
15.0%5.0%5.0%5.0%3.0%
Cardiovascular Portfolio — Organic Revenue Growth YoY (%)(%)
18.9%10.1%10.6%9.3%7.0%7.8%5.0%5.6%6.9%4.0%5.1%4.8%
Cardiovascular Portfolio — Foreign Currency Impact ($M)($M)
21124994668-37-3816-39-282831
Cardiovascular Portfolio — Reported Revenue Growth YoY (%)(%)
19.5%13.8%13.8%10.8%9.3%6.6%3.7%6.1%5.5%-5.2%6.1%5.9%
Cardiovascular Portfolio — U.S. Revenue ($M)($M)1
1,8531,7751,5891,5921,4791,5631,4051,4341,4031,4481,3731,427
Cardiovascular Portfolio — International Revenue ($M)($M)2
2,0742,0231,8681,8441,8061,7731,6321,6681,6041,6821,5561,496
Cardiovascular Portfolio — Non-U.S. Developed Markets Revenue (Legacy through FY2024Q4, $M)($M)1
1,039950912
Cardiovascular Portfolio — Emerging Markets Revenue (Legacy through FY2024Q4, $M)($M)1
643607584
Cardiac Rhythm & Heart Failure (CRHF — Legacy through FY2026Q4) — Worldwide Revenue ($M)($M)5
2,1101,8561,8251,7121,7331,5451,5781,5351,5871,4701,492
Structural Heart & Aortic (SHA — Legacy through FY2026Q4) — Worldwide Revenue ($M)($M)5
1,002929956930944874881856883843819
Coronary & Peripheral Vascular (CPV — Legacy through FY2026Q4) — Worldwide Revenue ($M)($M)5
685672655643659618643616660616613
Neuroscience Portfolio — Worldwide Revenue ($M)($M)7
2,6782,7512,5582,5622,4272,6202,4582,4512,3172,5452,3552,288
Neuroscience Portfolio — Organic Revenue Growth YoY (%)(%)
9.3%3.0%2.5%3.9%3.1%3.7%5.2%6.7%5.3%6.5%4.3%4.2%
Neuroscience Portfolio — Foreign Currency Impact ($M)($M)
652381527-18-2110-18-211010
Neuroscience Portfolio — Reported Revenue Growth YoY (%)(%)
10.3%5.0%4.1%4.5%4.3%2.9%4.4%7.1%4.4%5.6%4.8%4.7%
Neuroscience Portfolio — U.S. Revenue ($M)($M)1
1,8131,8121,7091,7301,6241,7821,6891,6771,5651,6921,5561,560
Neuroscience Portfolio — International Revenue ($M)($M)2
864938849832803838769774752853799728
Neuroscience Portfolio — Non-U.S. Developed Markets Revenue (Legacy through FY2024Q4, $M)($M)1
482442399
Neuroscience Portfolio — Emerging Markets Revenue (Legacy through FY2024Q4, $M)($M)1
371357329
Cranial & Spinal Technologies (CST) — Worldwide Revenue ($M)($M)6
1,3651,4031,3101,2991,2111,3421,2501,2341,1471,2911,2041,157
Core Spine Hardware — Global Organic Revenue Growth YoY (%)(%)
14.0%6.0%8.0%8.0%
Cranial & Spinal Technologies (CST) — Organic Revenue Growth YoY (%)(%)
12.9%3.3%3.7%4.7%4.5%4.4%4.6%6.4%4.8%8.7%6.5%6.7%
Cranial & Spinal Technologies (CST) — Foreign Currency Impact ($M)($M)
-21813612-7-93-9-1134
Cranial & Spinal Technologies (CST) — Reported Revenue Growth YoY (%)(%)
12.8%4.6%4.8%5.2%5.5%3.9%3.8%6.7%4.0%7.8%6.7%7.0%
Cranial & Spinal Technologies (CST) — U.S. Revenue ($M)($M)1
1,0161,031977966890999943926855936875863
Cranial & Spinal Technologies (CST) — International Revenue ($M)($M)2
349372333332320343307308292356329293
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — Worldwide Revenue ($M)($M)5
774806746744702759732737713778726705
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — Organic Revenue Growth YoY (%)(%)
7.4%3.4%-0.2%0.3%-2.7%-1.6%1.9%3.9%3.4%3.1%3.4%2.6%
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — Foreign Currency Impact ($M)($M)
6211559-7-85-7-931
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — Reported Revenue Growth YoY (%)(%)
10.2%6.2%1.9%0.9%-1.5%-2.5%0.8%4.6%2.5%2.0%3.9%2.8%
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — U.S. Revenue ($M)($M)
447431402409393431419418398439407403
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — International Revenue ($M)($M)2
326374343335309328313319314339319302
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — Worldwide Revenue ($M)($M)5
539542503520514520476480457475425426
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — Organic Revenue Growth YoY (%)(%)
3.3%1.7%3.6%7.3%8.6%10.2%12.9%12.1%9.6%6.0%0.2%0.5%
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — Foreign Currency Impact ($M)($M)
2131057-4-42-3-145
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — Reported Revenue Growth YoY (%)(%)
4.7%4.3%5.8%8.3%10.2%9.3%12.0%12.6%8.9%5.8%1.2%1.7%
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — U.S. Revenue ($M)($M)1
350350330355341352327333312317275293
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — International Revenue ($M)($M)2
189191173165174167149146146158150133
Medical Surgical Portfolio — Worldwide Revenue ($M)($M)7
2,2792,3882,1732,1712,0732,2122,0722,1281,9962,1982,1122,103
Medical Surgical Portfolio — Organic Revenue Growth YoY (%)(%)
10.2%5.1%2.7%1.3%2.4%2.0%-0.4%0.7%1.0%4.5%2.9%5.6%
Medical Surgical Portfolio — Foreign Currency Impact ($M)($M)
1581612740-30-3210-29-222027
Medical Surgical Portfolio — Reported Revenue Growth YoY (%)(%)
10.0%8.0%4.9%2.1%4.4%0.6%-1.9%1.2%-0.4%3.5%3.9%7.0%
Medical Surgical Portfolio — U.S. Revenue ($M)($M)1
9821,021929943884946893944881954947948
Medical Surgical Portfolio — International Revenue ($M)($M)2
1,2971,3661,2441,2281,1881,2661,1801,1831,1151,2441,1641,155
Medical Surgical Portfolio — Non-U.S. Developed Markets Revenue (Legacy through FY2024Q4, $M)($M)1
805758740
Medical Surgical Portfolio — Emerging Markets Revenue (Legacy through FY2024Q4, $M)($M)1
439429438
Surgical & Endoscopy — Worldwide Revenue ($M)($M)5
1,7401,8201,6541,6791,6011,7091,5961,6491,5441,7051,6161,641
Surgical & Endoscopy — Organic Revenue Growth YoY (%)(%)
9.0%3.5%1.4%1.1%2.3%1.7%0.4%1.3%5.0%3.4%6.8%
Surgical & Endoscopy — Foreign Currency Impact ($M)($M)
1469512332-25-269-22-151825
Surgical & Endoscopy — Reported Revenue Growth YoY (%)(%)
8.7%6.5%3.6%1.8%4.4%0.2%-1.2%0.5%-0.1%4.1%4.5%8.5%
Surgical & Endoscopy — U.S. Revenue ($M)($M)1
671694634665622668623675630679663688
Surgical & Endoscopy — International Revenue ($M)($M)2
1,0701,1261,0201,0149801,0419739749151,026953953
Acute Care & Monitoring — Worldwide Revenue ($M)($M)5
539568519493471503476478452492495462
Acute Care & Monitoring — Organic Revenue Growth YoY (%)(%)
14.2%10.5%7.0%2.0%2.6%3.1%-2.8%3.3%-0.1%2.5%
Acute Care & Monitoring — Foreign Currency Impact ($M)($M)
1121048-5-51-6-6
Acute Care & Monitoring — Reported Revenue Growth YoY (%)(%)
14.4%12.9%9.1%3.0%4.3%2.1%-3.9%3.6%-1.5%1.2%
Acute Care & Monitoring — U.S. Revenue ($M)($M)1
311328295278263278269269251275284260
Acute Care & Monitoring — International Revenue ($M)($M)2
228240224214209225206209200217211202
Cardiovascular — Segment R&D Expense ($M)($M)4
303273284299280259248256257
Cardiovascular — Segment SG&A Expense ($M)($M)
1,2691,1881,1291,1431,0601,0121,0101,021978
Cardiovascular — Segment Depreciation Expense ($M)($M)
716766566458565655
Cardiovascular — Segment Other Operating Expense ($M)($M)
14-1-14-17-15-14-14-7-6
Cardiovascular — Segment Goodwill Balance ($M)($M)
8,5838,6028,0378,0288,0458,0177,9297,9707,9777,9667,9067,849
Neuroscience — Segment R&D Expense ($M)($M)4
163139153167157149152158153
Neuroscience — Segment SG&A Expense ($M)($M)
922875841874831813820834808
Neuroscience — Segment Depreciation Expense ($M)($M)
788580797772737165
Neuroscience — Segment Other Operating Expense ($M)($M)
131312921212-411
Neuroscience — Segment Goodwill Balance ($M)($M)
12,67311,77711,75711,73811,75411,71611,61111,66811,65411,64411,67411,634
Medical Surgical — Segment R&D Expense ($M)($M)4
189163174181169169164171162
Medical Surgical — Segment SG&A Expense ($M)($M)
681650628627605593605609591
Medical Surgical — Segment Depreciation Expense ($M)($M)
655662535453515149
Medical Surgical — Segment Other Operating Expense ($M)($M)
556214455
Medical Surgical — Segment Goodwill Balance ($M)($M)
19,67519,95319,84219,78819,95219,74819,02519,26819,19819,12119,32519,084
Corporate & Shared Functions — Depreciation Expense ($M)($M)
696868616462575753
Remaining Performance Obligations / Contracted Backlog ($M)($M)3
400400400300400300400400400500500500
Deferred Revenue / Customer Contract Liabilities ($M)($M)1
500500468451442446462467461453447435
Revenue Recognized from Opening Contract Liability Balance ($M)($M)
140858594135695588108505892
Collaborative Arrangement Revenue ($M)($M)
123436373648504638
Allowance for Credit Losses on Accounts Receivable ($M)($M)
203190207200204199204195170173180177
Inventories by Production Stage — Total ($M)($M)3
6,2155,9516,3096,1565,8865,4765,6105,4795,4145,2175,7265,754
Finished Goods Inventory ($M)($M)
4,1214,0754,1944,1954,0223,7793,7403,7293,7323,6683,7993,775
Work in Process (WIP) Inventory ($M)($M)
900800883853792744782728696642788833
Raw Materials & Supplies Inventory ($M)($M)
1,1941,0761,2321,1081,0729531,0891,0229869071,1391,147
Intangible Asset Amortization Expense ($M)($M)9
412436441463459557416413414400419425
Quarterly Share Repurchases — Total Shares Purchased (millions)(M)3
2.774.510.923.301.392.911.932.8830.319.51.602.34
Stock-Based Compensation Expense by Award Type ($M)($M)5
1259595182868998159839085146
Unrecognized Tax Benefits (UTB) Balance ($M)($M)2
2,9003,0002,9002,9002,9002,9022,9002,9002,8002,8242,8002,800
Non-GAAP Operating Profit ($M)($M)10
2,3162,5002,1772,1622,0162,4862,1692,0411,9532,3112,0422,009
MiniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M)($M)19
843837790752723724687682623
MiniMed — Organic Revenue Growth YoY (%)(%)
15.8%8.7%8.6%7.8%
MiniMed — U.S. Net Sales ($M)($M)
240238242224212234231227211
MiniMed — International Net Sales ($M)($M)
603599548527511489456455412
MiniMed — Adjusted Standalone EBITDA ($M)($M)
83154127117851181078768
MiniMed — Adjusted EBITDA ($M)($M)
83-168978508373
MiniMed — Adjusted Gross Profit ($M)($M)
471487457434409411401
MiniMed — Adjusted Standalone Operating Income ($M)($M)
-68-5374486066479
MiniMed — Adjusted Standalone Net Income ($M)($M)
-53-4459384853377
MiniMed — GAAP Gross Profit ($M)($M)
465480362428409405395386342
MiniMed — GAAP R&D Expense ($M)($M)
11599114111125107112112105
MiniMed — GAAP SG&A Expense ($M)($M)
312299309293283276268271265
MiniMed — GAAP Operating Income / (Loss) ($M)($M)
5-91-10016-13-148217-27
MiniMed — GAAP Net Income / (Loss) ($M)($M)
0-183-111-5-16-168-7-5-19
MiniMed — Standalone Inventories ($M)($M)3
356341408311
MiniMed — Finished Goods Inventory ($M)($M)
193179199185
MiniMed — Work in Process Inventory ($M)($M)
35344438
MiniMed — Raw Materials Inventory ($M)($M)
12812816487
MiniMed — Standalone Remaining Performance Obligations ($M)($M)
463923
MiniMed — Standalone Contract Liabilities ($M)($M)
19191715
MiniMed — Customer Refund & Return Liabilities ($M)($M)
42454851
MiniMed — Property, Plant & Equipment, Net ($M)($M)
736711701706
MiniMed — Goodwill ($M)($M)
2,3002,3002,3002,300
FDA 510(k) Premarket Clearances — Medtronic1
91212893767738
FDA 510(k) Premarket Clearances — U.S. Industry Total
889835736823882767812814793750780941
FDA Premarket Approvals (PMA & Supplements) — Medtronic1
1141689313514712915995120132147139
FDA Premarket Approvals (PMA & Supplements) — U.S. Industry Total
616641434613597564607569575486582600
FDA Medical Device Recall Events — Medtronic1
281810661812114291614
FDA Device Enforcement Reports — Medtronic
23171067181111438238
FDA MAUDE Adverse Event Reports — Medtronic Total4
97,049104,15184,369101,86581,65966,22874,53967,79869,11064,20470,94973,691
ClinicalTrials.gov Newly Started Studies — Medtronic
12141115917108591210
Cardiovascular — Segment Revenue ($M, DB)($M)3
3,9273,7973,4573,4363,2853,3363,0373,1023,0073,1292,9292,923
Neuroscience — Segment Revenue ($M, DB)($M)3
2,6782,7512,5582,5622,4272,6202,4582,4512,3172,5452,3552,288
Medical Surgical — Segment Revenue ($M, DB)($M)3
2,2792,3872,1732,1712,0732,2112,0722,1281,9962,1982,1122,103
Diabetes — Segment Revenue ($M, DB)($M)
843838796757721728694686647659640610
United States — Geographic Revenue ($M, DB)($M)2
4,9064,8694,4934,5164,2244,5474,2374,3044,0824,3434,1204,175
Consolidated Net Sales / Revenue ($M, DB)($M)9
9,7569,8079,0178,9618,5788,9278,2928,4037,9158,5898,0897,984
Total Assets ($M, DB)($M)8
93,30693,02891,48591,34690,97291,68089,97390,04289,74989,98190,83690,087
Operating Cash Flow ($M, DB)($M)3
1,7932,5732,7449251,0882,5282,5729589862,7772,474661

10 metrics have no data in the last 12 quarters — .

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics
  • Core Operational & Franchise KPIs (Groups 1–2): Diabetes hardware unit volume (Worldwide New Pumps Sold in thousands), Global CGM Attachment Rate (%), recurring sensor/consumable vs. pump hardware revenue mix, Consolidated Gross Margin Pricing Benefit (bps), flagship franchise organic growth (Cardiac Ablation Solutions / PFA, Cardiac Rhythm Management, Core Spine), and all active + legacy Operating Divisions across Worldwide, U.S., and International markets.
  • Cardiovascular Q1 FY2027 Reorganization & Legacy Geography (Step 5): In Q1 FY2027 (14-week quarter ended July 31, 2026), Medtronic reorganized Cardiovascular from 3 divisions (CRHF, SHA, CPV) into 4 divisions (EP Therapies, IC Therapies, CV Surgery, PV Health) without Q2–Q4 FY2026 restated quarters yet; the 3 legacy divisions are retained through FY2026Q4 while the 4 new divisions (<3 consecutive quarters) are listed in excluded. Similarly, Non-U.S. Developed & Emerging Markets revenue/organic growth are retained as legacy rows through FY2024Q4 alongside International division tables (FY2024Q1–FY2027Q1).
  • Consolidated − Standalone Assessment (Step 3 & Step 4): Medtronic plc files consolidated financial statements in Form 10-K/10-Q without SEC Schedule I parent-only financial statements; in its Irish Statutory Reports, parent Medtronic plc is a pure holding company (zero operating turnover). Therefore consolidated − parent subtraction is not applicable. Instead, listed subsidiary MiniMed Group, Inc. (Nasdaq: MMED, CIK 0002062583 — IPO March 2026, split-off completed Oct 19, 2026) and Medtronic Limited (UK Co. 01070807) are tracked directly from their self-reported filings in Group 6.
  • Period Splitting (Step 4): Only YTD subtraction (YTD − prior YTD and FY − 9M / Q4 = full year − nine months) is used where 10-K/10-Q/8-K report cumulative year-to-date cash flows or segment/XBRL totals. Zero self-computed ratios, margins, YoY rates, or sums exist anywhere in output/kpis.json.

Not shown because recent periods are missing (88)

  • MiniMed Worldwide Installed Pump Users (~659,000 users) — Disclosed only for a single period (FY2026) as '~659K' / 'more than 650,000' (bound / <3 periods); excluded per Step 5.
  • Annual Patients Served Worldwide ('78M+', '79M+', '82M+') — Disclosed only with '+' lower-bound qualifier in Earnings Presentations and Letters; excluded per Step 5 bound rule.
  • Cardiac Ablation Solutions FY2026Q1 Global Growth ('nearly 50%') & U.S. Growth ('over 70%') — Qualified as bounds in Q1 FY26; series starts at FY2026Q2 where exact point figures (71%, 80%, 78%, 88%) are published.
  • Organizational Health Survey Employee Response Rate ('more than 88%' in FY2025 vs. 87% in FY2026) — FY2025 disclosed only as bound ('more than 88%'), leaving <2 consecutive point years.
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Foreign Currency Impact ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Reported Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — U.S. Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — U.S. Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — U.S. Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — International Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — International Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — International Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — International Foreign Currency Impact ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — International Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Foreign Currency Impact ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Reported Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — U.S. Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — U.S. Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — U.S. Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — International Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — International Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — International Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — International Foreign Currency Impact ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — International Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Foreign Currency Impact ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Reported Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — U.S. Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — U.S. Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — U.S. Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — International Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — International Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — International Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — International Foreign Currency Impact ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — International Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Foreign Currency Impact ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Reported Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — U.S. Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — U.S. Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — U.S. Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — International Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — International Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — International Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — International Foreign Currency Impact ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — International Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Specialty Therapies (Neurovascular, ENT & Pelvic Health) — Worldwide Revenue ($M) › Specialty Therapies (Neurovascular, ENT & Pelvic Health) — U.S. Revenue ($M) › Specialty Therapies (Neurovascular, ENT & Pelvic Health) — U.S. Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Surgical Innovations (Legacy through FY2023Q4) — Worldwide Revenue ($M) › Surgical Innovations (Legacy through FY2023Q4) — U.S. Revenue ($M) › Surgical Innovations (Legacy through FY2023Q4) — U.S. Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Respiratory, Gastrointestinal & Renal (Legacy through FY2023Q4) — Worldwide Revenue ($M) › Respiratory, Gastrointestinal & Renal (Legacy through FY2023Q4) — U.S. Revenue ($M) › Respiratory, Gastrointestinal & Renal (Legacy through FY2023Q4) — U.S. Organic Revenue Growth YoY (%)
  • Portfolio R&D, SG&A, Depreciation & Goodwill (ASU 2023-07 Non-DB XBRL) › Diabetes — Segment R&D Expense ($M) › Diabetes — Segment SG&A Expense ($M)
  • Portfolio R&D, SG&A, Depreciation & Goodwill (ASU 2023-07 Non-DB XBRL) › Diabetes — Segment R&D Expense ($M) › Diabetes — Segment Depreciation Expense ($M)
  • Portfolio R&D, SG&A, Depreciation & Goodwill (ASU 2023-07 Non-DB XBRL) › Diabetes — Segment R&D Expense ($M) › Diabetes — Segment Other Operating Expense ($M)
  • Portfolio R&D, SG&A, Depreciation & Goodwill (ASU 2023-07 Non-DB XBRL) › Diabetes — Segment R&D Expense ($M) › Diabetes — Segment Goodwill Balance ($M)
  • Portfolio R&D, SG&A, Depreciation & Goodwill (ASU 2023-07 Non-DB XBRL) › Diabetes — Segment R&D Expense ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Statutory Provisions for Liabilities — Total ($M) › Customer Rebates Provision Balance ($M) › U.S. GAAP Rebate Liability Offset Against Accounts Receivable ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Statutory Provisions for Liabilities — Total ($M) › Customer Rebates Provision Balance ($M) › U.S. GAAP Rebate Liability in Other Accrued Expenses ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Statutory Provisions for Liabilities — Total ($M) › MCS Product Exit Provision (FY2022–FY2023, $M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M) › Manufacturing & R&D Equipment ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M) › Computer Software & Enterprise Systems ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M) › Buildings & Leasehold Improvements ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M) › Construction in Progress — Capacity Expansion ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M) › Land & Land Improvements ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M) › Operating Lease Cash Payments ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M) › ROU Assets Obtained in Exchange for New Operating Leases ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M) › Operating Lease Weighted-Average Discount Rate (%)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M) › Undiscounted Lease Commitments — Year +1 ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M) › Undiscounted Lease Commitments — Thereafter (>5 Years, $M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Unrecognized Tax Benefits (UTB) Balance ($M) › Deferred Tax Assets Valuation Allowance ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Unrecognized Tax Benefits (UTB) Balance ($M) › U.S. Defined Benefit Pension Projected Benefit Obligation ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Unrecognized Tax Benefits (UTB) Balance ($M) › U.S. Defined Benefit Pension Fair Value of Plan Assets ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Unrecognized Tax Benefits (UTB) Balance ($M) › Non-U.S. Defined Benefit Pension Projected Benefit Obligation ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Unrecognized Tax Benefits (UTB) Balance ($M) › Non-U.S. Defined Benefit Pension Fair Value of Plan Assets ($M)
  • Global Workforce, Manufacturing Space, Compensation & Sustainability (DEF 14A / Irish Statutory / 10-K / Form SD) › Scope 1 & 2 GHG Emissions Intensity Reduction vs. FY2020 Baseline (%) › Product Innovation Vitality Index — Revenue from Products Released in Prior 36M (%)
  • Global Workforce, Manufacturing Space, Compensation & Sustainability (DEF 14A / Irish Statutory / 10-K / Form SD) › Scope 1 & 2 GHG Emissions Intensity Reduction vs. FY2020 Baseline (%) › Aggregate Product Complaint Rate Reduction vs. FY2020 Baseline (%)
  • Subsidiaries Self-Reported Filings (MiniMed Group, Inc. & Medtronic Limited UK) › MiniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M) › MiniMed — U.S. Net Sales ($M) › MiniMed — U.S. Organic Growth (%)
  • Subsidiaries Self-Reported Filings (MiniMed Group, Inc. & Medtronic Limited UK) › MiniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M) › MiniMed — International Net Sales ($M) › MiniMed — International Organic Growth (%)
  • Subsidiaries Self-Reported Filings (MiniMed Group, Inc. & Medtronic Limited UK) › MiniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M) › MiniMed — Operating Cash Flow ($M)
  • Subsidiaries Self-Reported Filings (MiniMed Group, Inc. & Medtronic Limited UK) › MiniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M) › MiniMed — Capital Expenditures ($M)
  • External MedTech Regulatory, Clinical, Federal Procurement & Sector Benchmarks › U.S. PPI: Surgical & Medical Instrument Manufacturing (Index) › U.S. Hospitals Quarterly Revenue — Census QSS ($M)
  • Reportable Segments & Geographic Context (Database) › Diabetes — Segment Revenue ($M, DB) › Diabetes — Segment Cost of Revenue ($M, DB)
  • Reportable Segments & Geographic Context (Database) › Diabetes — Segment Revenue ($M, DB) › Diabetes — Segment Operating Income ($M, DB)
  • Reportable Segments & Geographic Context (Database) › Diabetes — Segment Revenue ($M, DB) › Diabetes — Segment Total Assets ($M, DB)
  • Reportable Segments & Geographic Context (Database) › Other Operating Segments — Revenue ($M, DB) › Other Operating Segments — Operating Income ($M, DB)
  • Reportable Segments & Geographic Context (Database) › Other Operating Segments — Revenue ($M, DB)
  • Reportable Segments & Geographic Context (Database) › United States — Geographic Revenue ($M, DB) › United States — Long-Lived Assets ($M, DB)
  • Reportable Segments & Geographic Context (Database) › United States — Geographic Revenue ($M, DB) › Ireland — Long-Lived Assets ($M, DB)
  • Reportable Segments & Geographic Context (Database) › United States — Geographic Revenue ($M, DB) › Other Countries ex-U.S. & Ireland — Long-Lived Assets ($M, DB)
  • Consolidated Financial Statements Context (Database) › Consolidated Net Sales / Revenue ($M, DB) › Gross Profit ($M, DB)
  • Consolidated Financial Statements Context (Database) › Consolidated Net Sales / Revenue ($M, DB) › GAAP Diluted EPS ($, DB)
  • Consolidated Financial Statements Context (Database) › Consolidated Net Sales / Revenue ($M, DB) › Weighted-Average Diluted Shares (millions, DB)
  • Consolidated Financial Statements Context (Database) › Consolidated Net Sales / Revenue ($M, DB) › Cash Dividends Declared per Ordinary Share ($, DB)
  • Consolidated Financial Statements Context (Database) › Operating Cash Flow ($M, DB) › Acquisitions, Net of Cash Acquired ($M, DB)

Data updated 2026-10-31.

Every KPI on its own page

Full history, chart, sources and a citation for each metric

Diabetes Hardware & Recurring Consumable Drivers (Core KPIs)

Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary)

Portfolio R&D, SG&A, Depreciation & Goodwill (ASU 2023-07 Non-DB XBRL)

Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges

Global Workforce, Manufacturing Space, Compensation & Sustainability (DEF 14A / Irish Statutory / 10-K / Form SD)

Subsidiaries Self-Reported Filings (MiniMed Group, Inc. & Medtronic Limited UK)

External MedTech Regulatory, Clinical, Federal Procurement & Sector Benchmarks

Reportable Segments & Geographic Context (Database)

Consolidated Financial Statements Context (Database)